<p>隨着全球市場繼續應對地緣政治緊張局勢和經濟變化，亞洲股票因其增長潛力而吸引了投資者的關注。在這種環境下，識別那些可能低於其公允價值交易的股票，可以為尋求利用市場低效的投資者提供機會。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>中基光電 (SZSE:300308)</td>
<td>CN¥585.76</td>
<td>CN¥1156.92</td>
<td>49.4%</td>
</tr>
<tr>
<td>浙江傑美電子科技 (SZSE:002859)</td>
<td>CN¥29.74</td>
<td>CN¥59.28</td>
<td>49.8%</td>
</tr>
<tr>
<td>TLB (KOSDAQ:A356860)</td>
<td>₩59100.00</td>
<td>₩116379.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>蘇寧易購 (SZSE:002024)</td>
<td>CN¥1.66</td>
<td>CN¥3.26</td>
<td>49%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩430000.00</td>
<td>₩851013.65</td>
<td>49.5%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1753.00</td>
<td>¥3431.97</td>
<td>48.9%</td>
</tr>
<tr>
<td>HD 可再生能源 (TWSE:6873)</td>
<td>NT$104.50</td>
<td>NT$207.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>國全食品 (上海) (SEHK:2517)</td>
<td>HK$3.87</td>
<td>HK$7.64</td>
<td>49.4%</td>
</tr>
<tr>
<td>Andes 科技 (TWSE:6533)</td>
<td>NT$241.00</td>
<td>NT$481.50</td>
<td>49.9%</td>
</tr>
<tr>
<td>Aidma 控股 (TSE:7373)</td>
<td>¥3210.00</td>
<td>¥6305.80</td>
<td>49.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 258 只被低估亞洲股票的完整列表。</p>
<p>我們將從我們的篩選結果中選取一些進行分析。</p>
<h2>南京諾唯贊生物科技 (SHSE:688105)</h2>
<p><strong>概述：</strong> 南京諾唯贊生物科技有限公司提供生命科學、生物醫學和體外診斷領域的技術解決方案，市值為 88.7 億人民幣。</p>
<p><strong>運營：</strong> 南京諾唯贊生物科技有限公司通過其在生命科學、生物醫學和體外診斷領域的技術解決方案產生收入。</p>
<p><strong>公允價值折扣估算：</strong> 32.6%</p>
<p>南京諾唯贊生物科技的交易價格為 22.3 元，顯著低於其估算公允價值 33.06 元，表明其基於現金流被低估。儘管截至 2025 年 9 月的九個月內淨收入下降至 662 萬元，但預計未來三年內收益將年均增長超過 80%，超出市場平均水平。然而，1.35% 的股息收益率缺乏收益或自由現金流的覆蓋。</p>
<ul>
<li>我們最近的增長報告指出，南京諾唯贊生物科技的商業前景樂觀。</li>
<li>點擊這裏閲讀我們的健康報告，深入瞭解南京諾唯贊生物科技的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688105 截至 2026 年 1 月的折現現金流</p>
<h2>安徽容知日新科技 (SHSE:688768)</h2>
<p><strong>概述：</strong> 安徽容知日新科技有限公司在中國提供預測性維護領域的機械狀態監測解決方案，市值為 44.7 億人民幣。</p>
<p><strong>運營：</strong> 安徽容知日新科技通過提供機械狀態監測解決方案在預測性維護行業中產生收入。</p>
<p><strong>公允價值折扣估算：</strong> 45.1%</p>
<p>安徽容知日新科技的交易價格為 50.81 元，顯著低於其估算公允價值 92.54 元，突顯其基於現金流的被低估。該公司截至 2025 年 9 月的九個月內淨收入為 2690 萬元，較去年大幅增長。預計收益將年均增長超過 30%，超出市場平均水平，儘管股息穩定性仍然是一個問題，且歷史記錄不穩定。</p>
<ul>
<li>我們編制的增長報告表明，安徽容知日新科技的未來前景可能向好。</li>
<li>點擊這裏查看我們報告中安徽容知日新科技的資產負債表健康狀況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688768 截至 2026 年 1 月的折現現金流</p>
<h2>貝克倫 (TSE:6532)</h2>
<p><strong>概述：</strong> 貝克倫公司在日本提供諮詢服務，市值約為 10.4 億日元。</p>
<p><strong>運營：</strong> 該公司通過其諮詢業務部門產生收入，金額為 1.3042 億日元。</p>
<p><strong>公允價值折扣估算：</strong> 34.5%</p>
<p>貝克倫的交易價格為 6828 日元，顯著低於其估算公允價值 10424.18 日元，突顯其基於現金流的被低估。預計該公司的收益在未來三年將年均增長超過 20%，超出市場平均水平。儘管與收益相比，收入增長預測較慢，但貝克倫的股本回報率仍然強勁。最近的領導層變動和股息增加可能會影響投資者情緒，但不會改變其基本估值吸引力。</p>
<ul>
<li>我們的收益增長報告揭示了貝克倫未來業績顯著增長的潛力。</li>
<li>點擊這裏探索我們在貝克倫資產負債表健康報告中的詳細分析。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TSE:6532 截至 2026 年 1 月的折現現金流</p>
<h2>讓它發生</h2>
<ul>
<li>開始您的投資之旅，查看我們基於現金流的 258 只被低估亞洲股票的選擇。</li>
<li>這些公司是否是您投資策略的一部分？使用 Simply Wall St 將您的持股整合到一個投資組合中，並利用我們的綜合分析工具獲取見解。</li>
<li>利用 Simply Wall St 掌控您的財務未來，為每位投資者提供國際市場的免費深入知識。</li>
</ul>
<h2>對其他可能性感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健股息支付者來多樣化您的投資組合，以應對潛在的市場波動。</li>
<li>通過分析師和管理層的樂觀展望，推動您的投資組合中顯示強勁增長潛力的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章性質較為一般。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

諾唯贊

容知日新

<p>被認為可能被低估的三隻亞洲股票包括：安徽容知日新，當前交易價格為 50.81 元，較其公允價值 92.54 元有 45.1% 的折扣；南京諾唯贊生物科技，當前交易價格為 22.3 元，較其公允價值 33.06 元有 32.6% 的折扣；以及 Baycurrent，當前交易價格為 6,828 日元，較其公允價值 10,424.18 日元有 34.5% 的折扣。這些公司在當前市場環境下展現出良好的增長潛力，使其成為尋求被低估投資機會的投資者的吸引對象</p>

<p>As global markets continue to navigate geopolitical tensions and economic shifts, Asian equities are capturing investor attention with their potential for growth. In this environment, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on market inefficiencies.</p>
<div class="lb-trans"><p>隨着全球市場繼續應對地緣政治緊張局勢和經濟變化，亞洲股票因其增長潛力而吸引了投資者的關注。在這種環境下，識別那些可能低於其公允價值交易的股票，可以為尋求利用市場低效的投資者提供機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Zhongji Innolight (SZSE:300308)</td>
<td>CN¥585.76</td>
<td>CN¥1156.92</td>
<td>49.4%</td>
</tr>
<tr>
<td>Zhejiang Jiemei Electronic And Technology (SZSE:002859)</td>
<td>CN¥29.74</td>
<td>CN¥59.28</td>
<td>49.8%</td>
</tr>
<tr>
<td>TLB (KOSDAQ:A356860)</td>
<td>₩59100.00</td>
<td>₩116379.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>Suning.com (SZSE:002024)</td>
<td>CN¥1.66</td>
<td>CN¥3.26</td>
<td>49%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩430000.00</td>
<td>₩851013.65</td>
<td>49.5%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1753.00</td>
<td>¥3431.97</td>
<td>48.9%</td>
</tr>
<tr>
<td>HD Renewable Energy (TWSE:6873)</td>
<td>NT$104.50</td>
<td>NT$207.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>Guoquan Food (Shanghai) (SEHK:2517)</td>
<td>HK$3.87</td>
<td>HK$7.64</td>
<td>49.4%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$241.00</td>
<td>NT$481.50</td>
<td>49.9%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3210.00</td>
<td>¥6305.80</td>
<td>49.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>中基光電 (SZSE:300308)</td>
<td>CN¥585.76</td>
<td>CN¥1156.92</td>
<td>49.4%</td>
</tr>
<tr>
<td>浙江傑美電子科技 (SZSE:002859)</td>
<td>CN¥29.74</td>
<td>CN¥59.28</td>
<td>49.8%</td>
</tr>
<tr>
<td>TLB (KOSDAQ:A356860)</td>
<td>₩59100.00</td>
<td>₩116379.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>蘇寧易購 (SZSE:002024)</td>
<td>CN¥1.66</td>
<td>CN¥3.26</td>
<td>49%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩430000.00</td>
<td>₩851013.65</td>
<td>49.5%</td>
</tr>
<tr>
<td>PeptiDream (TSE:4587)</td>
<td>¥1753.00</td>
<td>¥3431.97</td>
<td>48.9%</td>
</tr>
<tr>
<td>HD 可再生能源 (TWSE:6873)</td>
<td>NT$104.50</td>
<td>NT$207.45</td>
<td>49.6%</td>
</tr>
<tr>
<td>國全食品 (上海) (SEHK:2517)</td>
<td>HK$3.87</td>
<td>HK$7.64</td>
<td>49.4%</td>
</tr>
<tr>
<td>Andes 科技 (TWSE:6533)</td>
<td>NT$241.00</td>
<td>NT$481.50</td>
<td>49.9%</td>
</tr>
<tr>
<td>Aidma 控股 (TSE:7373)</td>
<td>¥3210.00</td>
<td>¥6305.80</td>
<td>49.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 258 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 258 只被低估亞洲股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我們將從我們的篩選結果中選取一些進行分析。</p>
</div><h2>Nanjing Vazyme Biotech (SHSE:688105)</h2>
<div class="lb-trans"><h2>南京諾唯贊生物科技 (SHSE:688105)</h2>
</div><p><strong>Overview:</strong> Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics, with a market cap of CN¥8.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 南京諾唯贊生物科技有限公司提供生命科學、生物醫學和體外診斷領域的技術解決方案，市值為 88.7 億人民幣。</p>
</div><p><strong>Operations:</strong> Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in the fields of life science, biomedicine, and in vitro diagnostics.</p>
<div class="lb-trans"><p><strong>運營：</strong> 南京諾唯贊生物科技有限公司通過其在生命科學、生物醫學和體外診斷領域的技術解決方案產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 32.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 32.6%</p>
</div><p>Nanjing Vazyme Biotech is trading at CNY 22.3, significantly below its estimated fair value of CNY 33.06, indicating it is undervalued based on cash flows. Despite a recent decrease in net income to CNY 6.62 million for the nine months ended September 2025, earnings are projected to grow substantially by over 80% annually and surpass average market growth within three years. However, the dividend yield of 1.35% lacks coverage by earnings or free cash flow.</p>
<div class="lb-trans"><p>南京諾唯贊生物科技的交易價格為 22.3 元，顯著低於其估算公允價值 33.06 元，表明其基於現金流被低估。儘管截至 2025 年 9 月的九個月內淨收入下降至 662 萬元，但預計未來三年內收益將年均增長超過 80%，超出市場平均水平。然而，1.35% 的股息收益率缺乏收益或自由現金流的覆蓋。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Nanjing Vazyme Biotech's business outlook.</li>
<li>Get an in-depth perspective on Nanjing Vazyme Biotech's balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告指出，南京諾唯贊生物科技的商業前景樂觀。</li>
<li>點擊這裏閲讀我們的健康報告，深入瞭解南京諾唯贊生物科技的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/66fe6daa-ec08-4fdc-888d-05bc7f5c64d9/chart/dcf?theme=light"/></p>
<p>SHSE:688105 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688105 截至 2026 年 1 月的折現現金流</p>
</div><h2>Anhui Ronds Science &amp; Technology (SHSE:688768)</h2>
<div class="lb-trans"><h2>安徽容知日新科技 (SHSE:688768)</h2>
</div><p><strong>Overview:</strong> Anhui Ronds Science &amp; Technology Incorporated Company offers solutions for machinery condition monitoring in the predictive maintenance sector in China, with a market cap of CN¥4.47 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 安徽容知日新科技有限公司在中國提供預測性維護領域的機械狀態監測解決方案，市值為 44.7 億人民幣。</p>
</div><p><strong>Operations:</strong> Anhui Ronds Science &amp; Technology generates its revenue from providing solutions for machinery condition monitoring within the predictive maintenance industry in China.</p>
<div class="lb-trans"><p><strong>運營：</strong> 安徽容知日新科技通過提供機械狀態監測解決方案在預測性維護行業中產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 45.1%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 45.1%</p>
</div><p>Anhui Ronds Science &amp; Technology is trading at CN¥50.81, significantly below its estimated fair value of CN¥92.54, highlighting its undervaluation based on cash flows. The company reported net income of CN¥26.9 million for the nine months ended September 2025, a substantial increase from the previous year. Earnings are forecast to grow significantly by over 30% annually, outpacing market averages, though dividend stability remains a concern with an unstable track record.</p>
<div class="lb-trans"><p>安徽容知日新科技的交易價格為 50.81 元，顯著低於其估算公允價值 92.54 元，突顯其基於現金流的被低估。該公司截至 2025 年 9 月的九個月內淨收入為 2690 萬元，較去年大幅增長。預計收益將年均增長超過 30%，超出市場平均水平，儘管股息穩定性仍然是一個問題，且歷史記錄不穩定。</p>
</div><ul>
<li>The growth report we've compiled suggests that Anhui Ronds Science &amp; Technology's future prospects could be on the up.</li>
<li>Take a closer look at Anhui Ronds Science &amp; Technology's balance sheet health here in our report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明，安徽容知日新科技的未來前景可能向好。</li>
<li>點擊這裏查看我們報告中安徽容知日新科技的資產負債表健康狀況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/8e84e37d-7e29-4ecd-9ce0-0fc7a438d4a3/chart/dcf?theme=light"/></p>
<p>SHSE:688768 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688768 截至 2026 年 1 月的折現現金流</p>
</div><h2>Baycurrent (TSE:6532)</h2>
<div class="lb-trans"><h2>貝克倫 (TSE:6532)</h2>
</div><p><strong>Overview:</strong> Baycurrent, Inc. offers consulting services in Japan and has a market cap of approximately ¥1.04 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 貝克倫公司在日本提供諮詢服務，市值約為 10.4 億日元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Consulting Business segment, which amounts to ¥130.42 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其諮詢業務部門產生收入，金額為 1.3042 億日元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 34.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 34.5%</p>
</div><p>Baycurrent is trading at ¥6,828, notably below its estimated fair value of ¥10,424.18, underscoring its undervaluation based on cash flows. The company's earnings are projected to grow over 20% annually for the next three years, surpassing market averages. Despite slower revenue growth forecasts compared to earnings, Baycurrent's return on equity remains robust. Recent leadership changes and dividend increases may impact investor sentiment but don't alter the fundamental valuation appeal.</p>
<div class="lb-trans"><p>貝克倫的交易價格為 6828 日元，顯著低於其估算公允價值 10424.18 日元，突顯其基於現金流的被低估。預計該公司的收益在未來三年將年均增長超過 20%，超出市場平均水平。儘管與收益相比，收入增長預測較慢，但貝克倫的股本回報率仍然強勁。最近的領導層變動和股息增加可能會影響投資者情緒，但不會改變其基本估值吸引力。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in Baycurrent's future results.</li>
<li>Click to explore a detailed breakdown of our findings in Baycurrent's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的收益增長報告揭示了貝克倫未來業績顯著增長的潛力。</li>
<li>點擊這裏探索我們在貝克倫資產負債表健康報告中的詳細分析。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/55152fb0-a8ba-4f7b-9b06-4f87acc73cb6/chart/dcf?theme=light"/></p>
<p>TSE:6532 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>TSE:6532 截至 2026 年 1 月的折現現金流</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Embark on your investment journey to our 258 Undervalued Asian Stocks Based On Cash Flows selection here.</li>
<li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li>
<li>Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.</li>
</ul>
<div class="lb-trans"><ul>
<li>開始您的投資之旅，查看我們基於現金流的 258 只被低估亞洲股票的選擇。</li>
<li>這些公司是否是您投資策略的一部分？使用 Simply Wall St 將您的持股整合到一個投資組合中，並利用我們的綜合分析工具獲取見解。</li>
<li>利用 Simply Wall St 掌控您的財務未來，為每位投資者提供國際市場的免費深入知識。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健股息支付者來多樣化您的投資組合，以應對潛在的市場波動。</li>
<li>通過分析師和管理層的樂觀展望，推動您的投資組合中顯示強勁增長潛力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章性質較為一般。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

3 只亞洲股票可能以低於公允價值最多 45.1% 的價格進行交易